Antibiotics US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Antibiotics. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Antibiotics US Medical PG Question 1: An 8-year-old girl is brought to the emergency room for a 6-hour history of fever, sore throat, and difficulty swallowing. Physical examination shows pooling of oral secretions and inspiratory stridor. Lateral x-ray of the neck shows thickening of the epiglottis and aryepiglottic folds. Throat culture with chocolate agar shows small, gram-negative coccobacilli. The patient's brother is started on the recommended antibiotic for chemoprophylaxis. Which of the following is the primary mechanism of action of this drug?
- A. Inhibition of the 50S ribosomal subunit
- B. Inhibition of prokaryotic topoisomerase II
- C. Inhibition of DNA-dependent RNA-polymerase (Correct Answer)
- D. Inhibition of the 30S ribosomal subunit
- E. Inhibition of peptidoglycan crosslinking
Antibiotics Explanation: ***Inhibition of DNA-dependent RNA-polymerase***
- The clinical picture strongly suggests **epiglottitis** caused by *Haemophilus influenzae type b* (Hib), characterized by **fever, sore throat, difficulty swallowing, pooling of oral secretions, inspiratory stridor**, and **epiglottic thickening** on X-ray.
- **Rifampin** is the recommended antibiotic for chemoprophylaxis in close contacts of Hib patients; its primary mechanism of action is to inhibit bacterial **DNA-dependent RNA polymerase**, thereby preventing **mRNA synthesis**.
*Inhibition of the 50S ribosomal subunit*
- This mechanism is characteristic of **macrolides** (e.g., azithromycin, erythromycin) and **clindamycin**, which are not the primary choice for Hib chemoprophylaxis.
- These drugs prevent **protein synthesis** by interfering with translocation or peptide bond formation on the larger ribosomal subunit.
*Inhibition of prokaryotic topoisomerase II*
- This is the mechanism of action for **fluoroquinolones** (e.g., ciprofloxacin), which are typically reserved for specific infections due to potential side effects in children.
- Fluoroquinolones interfere with **DNA replication** and **transcription** by preventing DNA unwinding and supercoiling.
*Inhibition of the 30S ribosomal subunit*
- This mechanism is associated with **tetracyclines** and **aminoglycosides** (e.g., doxycycline, gentamicin).
- These antibiotics block **protein synthesis** by preventing tRNA attachment or causing misreading of mRNA.
*Inhibition of peptidoglycan crosslinking*
- This describes the mechanism of **beta-lactam antibiotics** (e.g., penicillin, amoxicillin, cephalosporins), which inhibit bacterial **cell wall synthesis**.
- While some beta-lactams are used to treat Hib infections, they are not the primary drug for **chemoprophylaxis**.
Antibiotics US Medical PG Question 2: A 37-year-old woman with a history of anorectal abscesses complains of pain in the perianal region. Physical examination reveals mild swelling, tenderness, and erythema of the perianal skin. She is prescribed oral ampicillin and asked to return for follow-up. Two days later, the patient presents with a high-grade fever, syncope, and increased swelling. Which of the following would be the most common mechanism of resistance leading to the failure of antibiotic therapy in this patient?
- A. Intrinsic absence of a target site for the drug
- B. Use of an altered metabolic pathway
- C. Production of beta-lactamase enzyme (Correct Answer)
- D. Altered structural target for the drug
- E. Drug efflux pump
Antibiotics Explanation: ***Production of beta-lactamase enzyme***
- The patient's symptoms of a rapidly worsening infection despite ampicillin treatment suggest the presence of a **beta-lactamase producing organism**. Ampicillin is a **beta-lactam antibiotic** that is inactivated by these enzymes.
- Anorectal abscesses and rapidly progressing soft tissue infections are often caused by **polymicrobial flora**, including staphylococci and enterococci, many of which can produce **beta-lactamase**.
*Intrinsic absence of a target site for the drug*
- While some bacteria inherently lack the target site for certain drugs (e.g., mycoplasma lacking a cell wall, thus being resistant to beta-lactams), this is less likely to be the **most common mechanism of acquired resistance** leading to treatment failure in a typical perianal infection.
- The rapid progression and failed initial treatment point towards an **acquired mechanism of resistance** rather than an intrinsic one.
*Use of an altered metabolic pathway*
- This mechanism, such as altered **folate synthesis pathways** in resistance to trimethoprim-sulfamethoxazole, is less common as the primary mechanism for ampicillin resistance.
- Ampicillin's mechanism of action primarily targets the **bacterial cell wall**, not a metabolic pathway in the same way.
*Altered structural target for the drug*
- This involves modifications to the **penicillin-binding proteins (PBPs)**, which are the targets of beta-lactam antibiotics like ampicillin. While a valid mechanism (e.g., in MRSA), the **production of beta-lactamase** is generally a more widespread and common cause of ampicillin failure, especially in infections involving mixed flora from the perianal region.
- Given the abrupt failure of ampicillin, **beta-lactamase inactivation** is a more immediate and common cause than a rapid mutational change in PBPs.
*Drug efflux pump*
- **Efflux pumps** actively remove antibiotics from the bacterial cell, contributing to resistance against various drug classes.
- While efflux pumps can play a role, the dominant mechanism for resistance to **ampicillin** in many common perianal pathogens is the **enzymatic degradation by beta-lactamases**.
Antibiotics US Medical PG Question 3: Three days after admission to the hospital following a motor vehicle accident, a 45-year-old woman develops a fever. A central venous catheter was placed on the day of admission for treatment of severe hypotension. Her temperature is 39.2°C (102.5°F). Examination shows erythema surrounding the catheter insertion site at the right internal jugular vein. Blood cultures show gram-positive, catalase-positive cocci that have a high minimum inhibitory concentration when exposed to novobiocin. Which of the following is the most appropriate pharmacotherapy?
- A. Clarithromycin
- B. Vancomycin (Correct Answer)
- C. Metronidazole
- D. Penicillin G
- E. Polymyxin B
Antibiotics Explanation: ***Vancomycin***
- The description of **gram-positive, catalase-positive cocci** that are **novobiocin-resistant** (high MIC) strongly points to **Staphylococcus epidermidis** or other coagulase-negative staphylococci. *S. epidermidis* is the most common cause of **catheter-related bloodstream infections** and is often **methicillin-resistant**, making **vancomycin** the drug of choice.
- The presence of erythema at the catheter site and fever in a patient with a central venous catheter indicates a **central line-associated bloodstream infection (CLABSI)**, for which empiric coverage with vancomycin is standard until sensitivities are known.
- The novobiocin resistance test helps differentiate *S. epidermidis* (resistant) from *S. saprophyticus* (sensitive).
*Clarithromycin*
- **Clarithromycin** is a macrolide antibiotic primarily used for respiratory tract infections and *Mycobacterium avium complex*.
- It is **not effective** against methicillin-resistant staphylococci and would not be appropriate for a suspected CLABSI.
*Metronidazole*
- **Metronidazole** is an antibiotic mainly used for **anaerobic bacterial infections** and certain parasitic infections.
- It has **no activity** against gram-positive cocci like staphylococci.
*Penicillin G*
- **Penicillin G** is a narrow-spectrum penicillin effective against some gram-positive cocci, like **Streptococcus pyogenes**.
- However, virtually all staphylococci, especially those causing hospital-acquired infections, are **resistant to penicillin G** due to beta-lactamase (penicillinase) production.
*Polymyxin B*
- **Polymyxin B** is an antibiotic primarily effective against **gram-negative bacteria**, particularly those with multi-drug resistance such as **Pseudomonas aeruginosa** and **Acinetobacter baumannii**.
- It has **no significant activity** against gram-positive cocci like staphylococci.
Antibiotics US Medical PG Question 4: You are a resident in the surgical ICU. One of the patients you are covering is a 35-year-old pregnant G1P0 in her first trimester admitted for complicated appendicitis and awaiting appendectomy. Your attending surgeon would like you to start the patient on moxifloxacin IV preoperatively. You remember from your obstetrics clerkship, however, that moxifloxacin is Pregnancy Category C, and animal studies have shown that immature animals exposed to fluoroquinolones like moxifloxacin may experience cartilage damage. You know that there are potentially safer antibiotics, such as piperacillin/tazobactam, which is in Pregnancy Category B. What should you do?
- A. Administer moxifloxacin since it is only Pregnancy Category C and, although studies may have revealed adverse effects in animals, there is no definite evidence that it causes risk in humans.
- B. Administer piperacillin/tazobactam instead of moxifloxacin without discussing with the attending since your obligation is to "first, do no harm" and both are acceptable antibiotics for complicated appendicitis.
- C. Discuss the adverse effects of each antibiotic with the patient, and then let the patient decide which antibiotic she would prefer.
- D. Wait to administer any antibiotics until you discuss your safety concerns with your attending. (Correct Answer)
- E. Administer moxifloxacin since the attending is the executive decision maker and had to know the patient was pregnant when deciding on an antibiotic.
Antibiotics Explanation: **Wait to administer any antibiotics until you discuss your safety concerns with your attending.**
- As a resident, you have a **professional and ethical obligation** to voice concerns about patient safety, especially regarding medication choices in vulnerable populations like pregnant women.
- Discussing your concerns with the attending physician allows for a **re-evaluation of the treatment plan** based on current evidence and patient-specific factors, ensuring the safest care.
*Administer moxifloxacin since it is only Pregnancy Category C and, although studies may have revealed adverse effects in animals, there is no definite evidence that it causes risk in humans.*
- While Category C means risk cannot be ruled out and benefits *may* outweigh risks, the presence of **known adverse effects in animal studies** and the availability of a safer alternative warrant reconsideration.
- Administering a drug with known potential harm without discussing alternatives or concerns goes against the principle of **prudence and patient safety**.
*Administer piperacillin/tazobactam instead of moxifloxacin without discussing with the attending since your obligation is to "first, do no harm" and both are acceptable antibiotics for complicated appendicitis.*
- While "first, do no harm" is paramount, **unilaterally changing a treatment plan** ordered by an attending physician is inappropriate and breaches professional hierarchy and communication protocols.
- The correct approach is to **communicate concerns** to the attending, allowing for a collaborative decision, rather than making independent substitutions.
*Discuss the adverse effects of each antibiotic with the patient, and then let the patient decide which antibiotic she would prefer.*
- While patient autonomy and informed consent are crucial, decisions about specific antibiotic choices, especially for a complicated condition like appendicitis, require **medical expertise**.
- As a resident, it is your role to present information but not to delegate such complex medical decisions to a patient, particularly when you yourself have **unresolved concerns** with the attending's order.
*Administer moxifloxacin since the attending is the executive decision maker and had to know the patient was pregnant when deciding on an antibiotic.*
- While the attending is the senior decision-maker, it is possible for **oversights or errors to occur**, even with experienced physicians.
- Assuming the attending "had to know" and therefore dismissing your own clinical judgment and knowledge of potential harm is **irresponsible** and compromises patient safety.
Antibiotics US Medical PG Question 5: You are treating a neonate with meningitis using ampicillin and a second antibiotic, X, that is known to cause ototoxicity. What is the mechanism of antibiotic X?
- A. It binds the 50S ribosomal subunit and inhibits formation of the initiation complex
- B. It binds the 30S ribosomal subunit and inhibits formation of the initiation complex (Correct Answer)
- C. It binds the 30S ribosomal subunit and reversibly inhibits translocation
- D. It binds the 50S ribosomal subunit and inhibits peptidyltransferase
- E. It binds the 50S ribosomal subunit and reversibly inhibits translocation
Antibiotics Explanation: ***It binds the 30s ribosomal subunit and inhibits formation of the initiation complex***
- The second antibiotic, X, is likely an **aminoglycoside**, such as **gentamicin** or **amikacin**, which are commonly used in combination with ampicillin for neonatal meningitis and are known to cause ototoxicity.
- Aminoglycosides exert their bactericidal effect by **irreversibly binding to the 30S ribosomal subunit**, thereby **inhibiting the formation of the initiation complex** and leading to misreading of mRNA.
*It binds the 50S ribosomal subunit and inhibits formation of the initiation complex*
- This mechanism is characteristic of **linezolid**, which targets the 50S ribosomal subunit to prevent the formation of the initiation complex.
- While linezolid can cause side effects, **ototoxicity** is less commonly associated with it compared to aminoglycosides, and it is not a primary drug for neonatal meningitis alongside ampicillin.
*It binds the 50S ribosomal subunit and inhibits peptidyltransferase*
- This is the mechanism of action for **chloramphenicol**, which inhibits **peptidyltransferase** activity on the 50S ribosomal subunit, preventing peptide bond formation.
- Although chloramphenicol can cause **ototoxicity** and **aplastic anemia**, its use in neonates is limited due to the risk of **Gray Baby Syndrome**.
*It binds the 30s ribosomal subunit and reversibly inhibits translocation*
- This describes the mechanism of action of **tetracyclines**, which reversibly bind to the 30S ribosomal subunit and prevent the attachment of aminoacyl-tRNA, thereby inhibiting protein synthesis.
- Tetracyclines are **contraindicated in neonates** due to their potential to cause **tooth discoloration** and **bone growth inhibition**, and ototoxicity is not their primary adverse effect.
*It binds the 50s ribosomal subunit and reversibly inhibits translocation*
- This mechanism of reversibly inhibiting translocation by binding to the 50S ribosomal subunit is characteristic of **macrolides** (e.g., erythromycin, azithromycin) and **clindamycin**.
- While some macrolides can cause **transient ototoxicity**, they are not typically the second antibiotic of choice for neonatal meningitis in combination with ampicillin, and clindamycin's side effect profile is different.
More Antibiotics US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
